Migraines Be Gone: AbbVie’s Atogepant Reduces Headache Frequency and Severity

Migraine headaches can be reduced in frequency and severity by atogepant, an oral therapy developed by AbbVie, according to data presented at the American Headache Society’s (AHS) Annual Scientific Meeting, June 3-6.